

ASX Release

Oventus \$2m capped Share Purchase Plan closes 6.3x oversubscribed, in addition to recent \$4.65m institutional Placement

Key highlights:

- Share Purchase Plan (SPP) closes, exceeding \$2m target, with \$12.64m in subscriptions received. SPP Offer capped at A\$2m, as per SPP prospectus
- Participating eligible shareholders will, subject to the SPP regulatory cap of A\$30,000, receive their pro-rated allocation
- In combination with institutional Placement which closed on 1 May 2020, the SPP takes total funds raised to A\$6.65m (following the pro-rated scale back)
- Investors who participated in the Placement and the SPP will receive a free attaching unlisted option on a 1-for-2 basis, exercisable at \$0.36 with an expiry date of 30 June 2021
- Funds raised will underpin the strong existing demand for Oventus' Lab in Lab business model with patient flow expected to accelerate as COVID-19 restrictions are gradually lifted in North America

Brisbane, Australia 18 June 2020: Obstructive Sleep Apnoea (OSA) treatment innovator, Oventus Medical Ltd (ASX: OVN) is pleased to announce that the Share Purchase Plan (SPP) announced on 1 May 2020 has successfully closed, with subscriptions received from shareholders, totalling \$12.64m. Once scaled back to the \$2m SPP cap and combined with the institutional placement (which closed 1 May 2020), the total offer raised approximately A\$6.65 million (before costs).

Under both the Placement and the SPP, the Company offered one (1) free attaching unlisted option for every two (2) new shares subscribed for (**Options**). The Shares under the Placement and the SPP had an issue price of \$0.24 each. The Options offered under the SPP and the Placement will have an exercise price of \$0.36 and will expire on 30 June 2021.

Funds raised from both the Placement and the SPP will be used to support expansion of Oventus' Lab in Lab business model to meet growing demand for the Company's products and services, with bookings continuing through COVID-19 and patient flow expected to accelerate as COVID-19 restrictions are gradually lifted in North America.

Oventus Chairman, Dr Mel Bridges said, *"We have been humbled by the level of support shown for Oventus by both institutions and our existing shareholders through this process. This new capital fortifies Oventus' balance sheet as we continue to make our way through the COVID-*

19 operating environment. Both the Placement and SPP were significantly over subscribed and we are extremely grateful for the strong support demonstrated through the capital raising."

Dr Chris Hart, CEO of Oventus added, *"During the pandemic period, we have continued to negotiate and sign agreements, and also implemented extensions to our business model, such as telehealth consultations, which have improved our operations and will become permanent."*

"Many facilities have started to re-open from the COVID-19 lockdown and we expect to see patient flow increasing into the September and December quarters. Our contract pipeline remains robust and expect trading to be near normal levels by the September quarter. This, combined with a number of solid existing agreements in the US and Canada and our sound balance sheet, means we are well placed with our commercialisation strategy as post-COVID-19 conditions continue to normalise."

In accordance with the terms of the SPP Offer, the Company will scale back applications received through the SPP on a pro-rata equal basis. The unallocated portion of applications for SPP Shares will be refunded following the scale back. An example of how the scale back will work is detailed below:

Shareholder subscription under SPP	Amount to be allocated following pro-rata scale back	Number of Shares and Options to be issued
\$30,000	\$4,745.90	19,774 Shares and 9,887 Options
\$20,000	\$3,163.93	13,183 Shares and 6,591 Options
\$15,000	\$2,372.95	9,887 Shares and 4,943 Options
\$10,000	\$1,581.97	6,591 Shares and 3,295 Options
\$7,500	\$1,186.47	4,943 Shares and 2,471 Options
\$3,000	\$474.59	1,977 Shares and 988 Options

As detailed in the Prospectus for the SPP, a fraction of a Share or Option under the SPP will be rounded down.

While the SPP was fully underwritten by Canaccord Genuity (Australia) Limited and Bell Potter Securities Limited (**Underwriters**), due to strong demand, no uptake of the underwriting offer was required. As a result, the SPP Prospectus timetable has been brought forward to enable new Shares under the SPP to be issued earlier.

The revised timetable for the issue of the Shares and Options under the SPP Offer and the Placement is detailed below:

Activity	Date
Issue Date Date of issue of the: <ul style="list-style-type: none"> • SPP Shares • SPP Options • Placement Options - as approved at the General Meeting dated 12 June 2020 • Placement Shares - to be issued to related parties as approved at the General Meeting dated 12 June 2020 	Thursday, 18 June 2020
Quotation Date Date of quotation for the: <ul style="list-style-type: none"> • SPP Shares • Placement Shares - to be issued to related parties as approved at the General Meeting dated 12 June 2020 	Friday, 19 June 2020
Holding Statements Date of dispatch of holding statements for the: <ul style="list-style-type: none"> • SPP Shares • SPP Options • Placement Options - as approved at the General Meeting dated 12 June 2020 • Placement Shares - to be issued to related parties as approved at the General Meeting dated 12 June 2020 	Monday, 22 June 2020
Pro-rata scale back refund Payment Date for refunds from the SPP following the pro-rata scale back.	Tuesday, 23 June 2020

Shareholders with questions in relation to the SPP may contact Oventus' share registry, Computershare Investor Services Pty Ltd, on 1300 552 270 (local call cost within Australia) or +61 3 9415 4000 at any time between 8:30am and 5:30pm (AEST), Monday to Friday (excluding public holidays.)

—ENDS—

For further information, please visit our website at www.o2vent.com or contact the individuals outlined below.

Dr Chris Hart, Managing Director and CEO: M: +61 409 647 496 or investors@oventus.com.au

Jane Lowe, IR Department: M: +61 411 117 774 or jane.lowe@irdepartment.com.au

About Oventus – see more at www.o2vent.com

Oventus is a Brisbane-based medical device company that is commercialising a unique treatment platform for sleep apnoea and snoring. The Company has a collaborative Sleep Physician/ Dental strategy that streamlines patients' access to treatment. The Oventus lab model incorporates digital technology via intra oral scanning to achieve operational efficiencies, accuracy and ultimately patient outcomes.

Unlike other oral appliances, Oventus O2Vent devices manage the entire upper airway via a unique and patented built-in airway. O2Vent devices allow for airflow to the back of the mouth while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue. The devices reduce airway collapsibility and manage mouth breathing while keeping the airway stable.

O2Vent devices are designed for any patient that is deemed appropriate for oral appliance therapy, but especially beneficial for the many people that suffer with nasal congestion, obstruction and mouth breathing. The O2Vent allows nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airway integrated in the appliance.

The ExVent™ is a valve accessory that fits into the open airway of the O2Vent Optima device, to augment traditional oral appliance therapy by stabilizing the airway. The ExVent valve contains air vents that open fully on inhalation for unobstructed airflow. The valve closes on exhalation, directing the air through the vents, creating the mild resistance or airway support required to keep the airway stable (known as PEEP, positive end expiratory pressure).

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea¹.

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnea, however many patients have difficulty tolerating CPAP². Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnea treatment³. The O2Vent Optima and ExVent provide a discreet and comfortable alternative to CPAP for the treatment of OSA.

¹ Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.

² Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003

³ Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.